Clinical trials: completed, sponsored by Bayer
Fibrosis, Renal Impairment
Safety of Gadovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate.
- Trial name
- GRIP (NCT00828737)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in Australia, Austria and 8 more
- Volunteers
- 927 people
- Sponsor
- Bayer
Pharmacokinetics
Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol
The clinical phase I study aims at investigating the conversion of the contraceptive compound norethisterone within the body towards the contraceptive compound ethinylestradiol.
- Trial name
- NCT02170038
- Testing
- Microgynon, Noristerat(BAY86-6308)
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Pneumonia
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
This study is to understand how the inhaled form of amikacin is spread throughout the human body and how it is eliminated from the body and to make sure that giving an inhaled form of Amikacin to patients is safe and well…
- Trial name
- NCT01021436
- Testing
- Amikacin inhalation solution (BAY41-6551)
- Where
- 6 sites in United States, France
- Volunteers
- 30 people
- Sponsor
- Bayer
Endometriosis
Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
This is a multi-center, randomized, double-blinded, placebo-controlled, parallel-group study (24-week treatment-comparison phase) with an open-label reference arm of active comparator (dienogest) followed by 28-week long-term…
- Trial name
- NCT01697111
- Testing
- EE20/DRSP(BAY86-5300), Dienogest
- Where
- 32 sites in Japan
- Volunteers
- 312 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made.
- Trial name
- STELLA (NCT01539681)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Italy
- Volunteers
- 234 people
- Sponsor
- Bayer
Hemophilia A
Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
The purpose of this study is to compare the pharmacokinetics of BAY81-8973 and Advate after intravenous administration.
- Trial name
- NCT02483208
- Testing
- BAY81-8973, Advate
- Where
- Bulgaria
- Volunteers
- 18 people
- Sponsor
- Bayer
Colorectal Neoplasms
Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
The purpose of this study is to assess if Regorafenib in combination with best supportive care will slow down tumor progression and result in increased survival in patients with metastatic colorectal cancer.
- Trial name
- CONCUR (NCT01584830)
- Testing
- Regorafenib (BAY73-4506)
- Where
- 25 sites in China, Hong Kong and 3 more
- Volunteers
- 204 people
- Sponsor
- Bayer
Atrial Fibrillation
Burden of Illness in Atrial Fibrillation
The overall goal of this retrospective registry study is to investigate the burden-of.illness in atrial fibrillation (AF) in Denmark.
- Trial name
- NCT02615587
- Testing
- Standard of care in AF in Denmark
- Where
- Denmark
- Volunteers
- 107,532 people
- Sponsor
- Bayer
Atopic Dermatitis
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
- Trial name
- NCT01228513
- Testing
- ZK245186
- Where
- 16 sites in United States, Japan
- Volunteers
- 263 people
- Sponsor
- Bayer
Oral Contraceptive, Headache
Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache
The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or…
- Conditions
- Oral Contraceptive, Headache, Pelvic Pain
- Trial name
- NCT00778609
- Testing
- EV/DNG (Qlaira, BAY86-5027)
- Where
- 63 sites in Australia, Finland and 7 more
- Volunteers
- 449 people
- Sponsor
- Bayer
Pharmacology, Clinical
Effect of Riociguat on Bone Metabolism
Investigation of the effect of Riociguat, administered as 2.5 mg IR-tablets TID over 14 days, on bone metabolism.
- Trial name
- NCT00855660
- Testing
- Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bayer
Ovarian Neoplasms
Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer
The purpose of this study is to determine if this epothilone leads to a response in patients with recurrent ovarian cancer that has progressed during, or in the last six months since a treatment of platinum-based chemotherapy.
- Trial name
- NCT00246688
- Testing
- Sagopilone (BAY86-5302 , ZK219477)
- Volunteers
- 63 people
- Sponsor
- Bayer
Contraception
FC Patch Comparator Study
The purpose of this study is to compare bleeding pattern and safety of contraceptive patch SH P00331F to a marketed comparator.
- Trial name
- NCT00185354
- Testing
- BAY86-5016, SH P00331F, SH P00331N
- Where
- 28 sites in Austria, Finland and 2 more
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Bayer
Carcinoma, Renal Cell
Sorafenib Dose Escalation in Renal Cell Carcinoma
Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of advanced kidney cancer. It is also currently being tested in various other cancers.
- Trial name
- NCT00618982
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 22 sites in France, Germany and 3 more
- Volunteers
- 83 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of BAY63-2521 in patients with pulmonary hypertension and stable treatment of sildenafil 20 mg.
- Trial name
- NCT00680654
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 5 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Bayer
Neoplasms
Investigation of Mass Balance of the Test Drug and Major Metabolites
The purpose of this study is to: a) Determine how the body takes up the test drug and distributes it into various body organs and tissues, how it processes the drug and how it ultimately removes it; and b) Examine how well the…
- Trial name
- NCT00432302
- Testing
- Sagopilone (BAY 86-5302, ZK 219477)
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bayer
Melanoma
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in…
- Trial name
- NCT00185302
- Testing
- Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)
- Volunteers
- 28 people
- Sponsor
- Bayer
Prostatic Neoplasms
PK in Pts With HRPC & Skeletal Metastes
Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight [b.w.] [=110 kBq/kg based on the 2015 National…
- Trial name
- NCT00667537
- Testing
- Radium-223 chloride (Xofigo®, BAY88-8223) injection
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Bayer
Breast Neoplasm
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) in patients with metastatic breast cancer helps to decrease or stop tumor growth.
- Trial name
- NCT00313248
- Testing
- Sagopilone (ZK 219477)
- Where
- 25 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Bayer
Hypertension, Essential
Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions
Randomized, open label, single dose, 4-way crossover study to investigate the bioequivalence of a new fixed dose combination tablet of nifedipine GITS and candesartan with the corresponding loose combination and to compare it…
- Trial name
- NCT01227603
- Testing
- Nifedipine-candesartan FDC (BAY 98-7106), Nifedipine GITS (Adalat LA, BAYA1040), Candesartan (Atacand)
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.